Baldwin Brothers LLC MA lifted its stake in Novo Nordisk A/S (NYSE:NVO – Get Rating) by 902.2% in the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 27,250 shares of the company’s stock after purchasing an additional 24,531 shares during the period. Baldwin Brothers LLC MA’s holdings in Novo Nordisk A/S were worth $3,688,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Cubist Systematic Strategies LLC lifted its stake in shares of Novo Nordisk A/S by 184.4% in the second quarter. Cubist Systematic Strategies LLC now owns 73,193 shares of the company’s stock valued at $8,156,000 after purchasing an additional 47,455 shares during the period. Resonant Capital Advisors LLC acquired a new position in Novo Nordisk A/S during the fourth quarter worth about $258,000. Keybank National Association OH raised its position in Novo Nordisk A/S by 11.1% during the third quarter. Keybank National Association OH now owns 27,511 shares of the company’s stock worth $2,741,000 after acquiring an additional 2,755 shares during the last quarter. Brookstone Capital Management raised its position in Novo Nordisk A/S by 6.1% during the fourth quarter. Brookstone Capital Management now owns 8,304 shares of the company’s stock worth $1,151,000 after acquiring an additional 479 shares during the last quarter. Finally, Old North State Trust LLC acquired a new position in Novo Nordisk A/S during the third quarter worth about $41,000. Institutional investors and hedge funds own 6.09% of the company’s stock.
Analyst Ratings Changes
A number of equities analysts have issued reports on the stock. JPMorgan Chase & Co. lifted their target price on shares of Novo Nordisk A/S from 925.00 to 1,100.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 3rd. Cowen lifted their target price on shares of Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. StockNews.com began coverage on shares of Novo Nordisk A/S in a report on Thursday, March 16th. They set a “strong-buy” rating for the company. Finally, Cowen lifted their price target on shares of Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, Novo Nordisk A/S currently has a consensus rating of “Moderate Buy” and a consensus target price of $697.78.
Novo Nordisk A/S Trading Up 0.9 %
Novo Nordisk A/S stock traded up $1.46 during trading on Friday, reaching $159.36. The company had a trading volume of 1,025,156 shares, compared to its average volume of 1,502,831. Novo Nordisk A/S has a 12-month low of $95.02 and a 12-month high of $160.91. The stock’s 50 day moving average price is $144.60 and its two-hundred day moving average price is $128.24. The firm has a market capitalization of $360.63 billion, a price-to-earnings ratio of 45.93, a PEG ratio of 1.70 and a beta of 0.48. The company has a debt-to-equity ratio of 0.29, a quick ratio of 0.69 and a current ratio of 0.89.
Novo Nordisk A/S (NYSE:NVO – Get Rating) last released its earnings results on Wednesday, February 1st. The company reported $0.83 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.81 by $0.02. Novo Nordisk A/S had a net margin of 31.44% and a return on equity of 73.39%. The firm had revenue of $6.60 billion during the quarter, compared to the consensus estimate of $6.74 billion. As a group, equities analysts expect that Novo Nordisk A/S will post 4.51 earnings per share for the current fiscal year.
Novo Nordisk A/S Increases Dividend
The firm also recently declared a semi-annual dividend, which was paid on Tuesday, April 4th. Shareholders of record on Monday, March 27th were given a dividend of $1.1887 per share. This represents a yield of 0.8%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. The ex-dividend date was Friday, March 24th. Novo Nordisk A/S’s payout ratio is 48.70%.
Novo Nordisk A/S Company Profile
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.